In a study of 761 lung cancer patients, Olaussen et al. 25 observed that almost half of them were negative for ERCC1 expression and that cisplatin treatment significantly prolonged the survival of patients with ERCC1-negative tumors but not that of those with ERCC1-positive tumors. Here, ERCC1 is linked to lung carcinoma.